8,579 Shares in Boston Scientific Co. (NYSE:BSX) Bought by Team Hewins LLC

Team Hewins LLC acquired a new position in shares of Boston Scientific Co. (NYSE:BSX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 8,579 shares of the medical equipment provider’s stock, valued at approximately $496,000.

Other institutional investors have also made changes to their positions in the company. US Bancorp DE grew its stake in Boston Scientific by 2.7% in the third quarter. US Bancorp DE now owns 443,737 shares of the medical equipment provider’s stock valued at $23,506,000 after acquiring an additional 11,641 shares during the period. ORG Partners LLC grew its stake in Boston Scientific by 612.5% in the third quarter. ORG Partners LLC now owns 1,140 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 980 shares during the period. Corient Private Wealth LLC grew its stake in Boston Scientific by 2.2% in the third quarter. Corient Private Wealth LLC now owns 178,806 shares of the medical equipment provider’s stock valued at $9,443,000 after acquiring an additional 3,776 shares during the period. Signaturefd LLC boosted its position in shares of Boston Scientific by 10.2% during the third quarter. Signaturefd LLC now owns 25,031 shares of the medical equipment provider’s stock worth $1,322,000 after buying an additional 2,317 shares during the period. Finally, NBC Securities Inc. acquired a new position in shares of Boston Scientific during the third quarter worth about $378,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Evercore ISI upped their price objective on Boston Scientific from $72.00 to $78.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th. Robert W. Baird upped their target price on Boston Scientific from $79.00 to $84.00 and gave the stock an “outperform” rating in a report on Thursday, April 25th. Oppenheimer upped their target price on Boston Scientific from $58.00 to $68.00 and gave the stock a “market perform” rating in a report on Thursday, February 1st. Royal Bank of Canada upped their target price on Boston Scientific from $78.00 to $82.00 and gave the stock an “outperform” rating in a report on Thursday, April 25th. Finally, Mizuho upped their target price on Boston Scientific from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, May 15th. Two investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.41.

Insider Activity

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $66.35, for a total transaction of $463,322.05. Following the completion of the transaction, the executive vice president now owns 53,788 shares in the company, valued at approximately $3,568,833.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $66.35, for a total value of $463,322.05. Following the transaction, the executive vice president now owns 53,788 shares in the company, valued at approximately $3,568,833.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP John Bradley Sorenson sold 16,351 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $69.30, for a total value of $1,133,124.30. Following the sale, the executive vice president now directly owns 50,638 shares in the company, valued at approximately $3,509,213.40. The disclosure for this sale can be found here. Insiders sold a total of 67,616 shares of company stock worth $4,819,057 in the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 1.7 %

NYSE:BSX traded up $1.28 during trading hours on Friday, hitting $75.66. 3,747,818 shares of the company were exchanged, compared to its average volume of 6,474,255. The stock has a market capitalization of $111.00 billion, a price-to-earnings ratio of 62.26, a price-to-earnings-growth ratio of 2.59 and a beta of 0.77. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. Boston Scientific Co. has a one year low of $48.35 and a one year high of $76.25. The company has a fifty day simple moving average of $70.42 and a 200 day simple moving average of $63.54.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.05. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. The business had revenue of $3.86 billion during the quarter, compared to analyst estimates of $3.68 billion. Sell-side analysts expect that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.